Pfizer Inc. has won regulatory approval for its hympavzi drug as a treatment for hemophilia A or B without inhibitors - making it the first antitissue-factor pathway inhibitor to be allowed for the ...

Only 13.4% immunocompromised adult US veterans younger than 50 years received the recombinant zoster vaccine by mid-2023, ...

The highly transmissable Covid-19 sub-variant, XEC has arrived in New Zealand, with one epidemologist concerned people will die if there's an outbreak of the new strain. This strain is a mix of two ...

The open-label, single-centre, single-arm trial will assess the safety and pharmacodynamics of DM199 in treating preeclampsia ...

Patenting Biopharmaceuticals In India. Legal News and Analysis - India - Intellectual Property - Conventus Law ...

The global Zika virus testing market is poised for substantial growth, according to a new forecast by Future Market Insights ...

The contract will provide an initial commitment of $19.6 million and up to $135.2 million over a six-year period, supporting ...

The FDA will decide on new drugs for rosacea, AADC deficiency, breast cancer, transthyretin amyloid cardiomyopathy, and biliary tract cancer.

Ocugen (OCGN) reported that the FDA has lifted the clinical hold on the investigational new drug application for the Phase 1 clinical ...

Novavax's vaccine is also authorized for use in the U.S., and is in line with guidance from the U.S. Food and Drug ...

Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and ...

“It might start becoming the top circulating lineage,” Rajnaranayam said, predicting XEC will take the rest of October and ...